Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Regen Theranostics Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's active prosecution is handled by 1 distinct examiner and is situated within 1 distinct art unit. This distribution shows a narrow administrative footprint for the company's current filings. For patent practitioners, this indicates that the company's immediate legal strategy is focused on a single point of contact within the patent office, which simplifies communication but increases the impact of that one examiner's specific preferences.
The busiest examiner, NOBLE, MARCIA STEPHENS, is responsible for 1 pending office action. The presence of 1 distinct art unit indicates that the biotechnology and pharmaceutical work is currently focused in one specialized regulatory group. This concentration suggests that the practitioner should tailor their arguments to the specific standards of this art unit, as there is no diversification across different technical groups at this time. Navigating this single-examiner environment requires a precise understanding of the examiner's previous rulings in the biotechnology sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18368240 | METHOD OF MANUFACTURING AUTOLOGOUS CARDIAC LINEAGE CELLS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18368240 | METHOD OF MANUFACTURING AUTOLOGOUS CARDIAC LINEAGE CELLS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Sep 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial